PT - JOURNAL ARTICLE AU - FUMINORI ISHII AU - YOICHIRO YOSHIDA AU - YASUSHI YAMAUCHI AU - NAOYA AISU AU - DAIBO KOJIMA AU - TOSHIYUKI MERA AU - DAISUKE KATO AU - TOSHIHIRO TANAKA AU - KEIKO NAITO AU - KOSEI YASUMOTO AU - TAKASHI KAMIGAKI AU - SHIGENORI GOTO AU - YOSHIHIRO HAMADA AU - SATOSHI NIMURA AU - SHOHTA KODAMA AU - SUGURU HASEGAWA TI - Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells DP - 2017 Jul 01 TA - Anticancer Research PG - 3933--3939 VI - 37 IP - 7 4099 - http://ar.iiarjournals.org/content/37/7/3933.short 4100 - http://ar.iiarjournals.org/content/37/7/3933.full SO - Anticancer Res2017 Jul 01; 37 AB - Background/Aim: Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. Patients and Methods: From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included. Results: The median age of the five patients (two men, three women) was 61.4 (range=56-75) years. The surgical procedure was partial hepatectomy in two, laparoscopic partial hepatectomy in two, and one case of partial hepatectomy with subsegmentectomy. There was no postoperative complication of Clavien-Dindo grade 3A or higher. One patient had multiple lung metastases. Conclusion: Hepatectomy after chemoimmunotherapy using activated αβ T-cells for CLM can be performed safely.